Jazz Pharmaceuticals PLC
JAZZ166.990USD
+0.990+0.60%
Handelsschluss 12/19, 16:00（ET）Kurse um 15 Minuten verzögert
10.14BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Jazz Pharmaceuticals PLC Unternehmen
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Jazz Pharmaceuticals PLC Informationen
BörsenkürzelJAZZ
Name des UnternehmensJazz Pharmaceuticals PLC
IPO-datumJan 18, 2012
CEOGala (Renee D)
Anzahl der mitarbeiter2800
WertpapierartOrdinary Share
GeschäftsjahresendeJan 18
AddresseFifth Floor, Waterloo Exchange
StadtDUBLIN
BörseNASDAQ OMX - NASDAQ BASIC
LandIreland
Postleitzahl- -
Telefon35316347800
Websitehttps://www.jazzpharma.com/
BörsenkürzelJAZZ
IPO-datumJan 18, 2012
CEOGala (Renee D)
Führungskräfte von Jazz Pharmaceuticals PLC
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.28%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
292.32K
-5.03%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.12K
-0.17%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
24.12K
-22.89%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
21.63K
-15.90%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
15.00K
--
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Director
Independent Director
13.92K
+13.93%
Ms. Anne O'Riordan
Ms. Anne O'Riordan
Independent Director
Independent Director
12.77K
+15.38%
Ms. Samantha Pearce
Ms. Samantha Pearce
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
9.24K
-5.88%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
7.11K
+31.50%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.28%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
292.32K
-5.03%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.12K
-0.17%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
24.12K
-22.89%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
21.63K
-15.90%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
15.00K
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Xywav
415.32M
39.72%
Epidiolex/epidyolex
251.73M
24.07%
Rylaze
100.66M
9.63%
Zepzelca
74.54M
7.13%
High-sodium oxybate AG royalty revenue
54.14M
5.18%
Andere
149.32M
14.28%
Nach RegionUSD
Name
Umsatz
Anteil
United States
936.28M
89.54%
Europe
82.76M
7.91%
All Others
26.67M
2.55%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Xywav
415.32M
39.72%
Epidiolex/epidyolex
251.73M
24.07%
Rylaze
100.66M
9.63%
Zepzelca
74.54M
7.13%
High-sodium oxybate AG royalty revenue
54.14M
5.18%
Andere
149.32M
14.28%
Aktionärsstatistik
Aktualisiert: Thu, Dec 4
Aktualisiert: Thu, Dec 4
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.68%
BlackRock Institutional Trust Company, N.A.
8.25%
Dimensional Fund Advisors, L.P.
4.67%
Capital World Investors
4.20%
LSV Asset Management
4.13%
Andere
69.06%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.68%
BlackRock Institutional Trust Company, N.A.
8.25%
Dimensional Fund Advisors, L.P.
4.67%
Capital World Investors
4.20%
LSV Asset Management
4.13%
Andere
69.06%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
50.91%
Investment Advisor/Hedge Fund
34.93%
Hedge Fund
10.56%
Research Firm
3.49%
Individual Investor
3.02%
Pension Fund
1.77%
Venture Capital
1.30%
Bank and Trust
0.85%
Sovereign Wealth Fund
0.09%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
1197
64.03M
105.38%
-5.21M
2025Q2
1199
63.76M
105.11%
-6.47M
2025Q1
1235
63.66M
105.15%
-6.35M
2024Q4
1202
62.66M
103.17%
-6.51M
2024Q3
1172
61.48M
99.60%
-6.16M
2024Q2
1167
61.28M
97.21%
-6.97M
2024Q1
1163
63.08M
101.15%
-2.43M
2023Q4
1156
61.76M
98.11%
-3.48M
2023Q3
1158
61.08M
96.76%
-4.05M
2023Q2
1197
61.00M
95.34%
-4.11M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
6.07M
10%
+73.43K
+1.22%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.22M
8.61%
+11.23K
+0.22%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
2.54M
4.18%
+209.41K
+8.99%
Jun 30, 2025
Capital World Investors
2.54M
4.19%
+616.73K
+31.99%
Jun 30, 2025
LSV Asset Management
2.55M
4.21%
+87.58K
+3.55%
Jun 30, 2025
State Street Investment Management (US)
1.94M
3.19%
-31.20K
-1.59%
Jun 30, 2025
EcoR1 Capital, LLC
1.71M
2.81%
--
--
Jun 30, 2025
JP Morgan Asset Management
1.55M
2.55%
+46.92K
+3.12%
Jun 30, 2025
Fuller & Thaler Asset Management Inc.
1.63M
2.69%
+297.95K
+22.39%
Jun 30, 2025
Columbia Threadneedle Investments (US)
1.54M
2.54%
+186.67K
+13.80%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Cambria Cannabis ETF
4.08%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
3.11%
iShares U.S. Pharmaceuticals ETF
3.08%
Invesco Pharmaceuticals ETF
2.94%
State Street SPDR S&P Pharmaceuticals ETF
2.83%
Abacus FCF International Leaders ETF
2.69%
First Trust NASDAQ Pharmaceuticals ETF
2.51%
Clough Hedged Equity ETF
2.4%
Alger Russell Innovation ETF
2.12%
VictoryShares Small Cap Free Cash Flow ETF
1.77%
Mehr Anzeigen
Cambria Cannabis ETF
Anteil4.08%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil3.11%
iShares U.S. Pharmaceuticals ETF
Anteil3.08%
Invesco Pharmaceuticals ETF
Anteil2.94%
State Street SPDR S&P Pharmaceuticals ETF
Anteil2.83%
Abacus FCF International Leaders ETF
Anteil2.69%
First Trust NASDAQ Pharmaceuticals ETF
Anteil2.51%
Clough Hedged Equity ETF
Anteil2.4%
Alger Russell Innovation ETF
Anteil2.12%
VictoryShares Small Cap Free Cash Flow ETF
Anteil1.77%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Jazz Pharmaceuticals PLC?
Die fünf größten Anteilseigner von Jazz Pharmaceuticals PLC sind:
The Vanguard Group, Inc. hält 6.07M Aktien, was 10.00% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 5.22M Aktien, was 8.61% der Gesamtaktien entspricht.
Dimensional Fund Advisors, L.P. hält 2.54M Aktien, was 4.18% der Gesamtaktien entspricht.
Capital World Investors hält 2.54M Aktien, was 4.19% der Gesamtaktien entspricht.
LSV Asset Management hält 2.55M Aktien, was 4.21% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 6.07M Aktien, was 10.00% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 5.22M Aktien, was 8.61% der Gesamtaktien entspricht.
Dimensional Fund Advisors, L.P. hält 2.54M Aktien, was 4.18% der Gesamtaktien entspricht.
Capital World Investors hält 2.54M Aktien, was 4.19% der Gesamtaktien entspricht.
LSV Asset Management hält 2.55M Aktien, was 4.21% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Jazz Pharmaceuticals PLC?
Die drei wichtigsten Anteilseigner-Typen von Jazz Pharmaceuticals PLC sind:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Dimensional Fund Advisors, L.P.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Dimensional Fund Advisors, L.P.
Wie viele Institutionen halten Anteile an Jazz Pharmaceuticals PLC (JAZZ)?
Mit Stand vom 2025Q3 halten 1197 Institutionen Anteile an Jazz Pharmaceuticals PLC, mit einem Gesamtmarktwert von etwa 64.03M, was 105.38% der Gesamtanteile entspricht. Im Vergleich zum 2025Q2 ist der institutionelle Aktienbesitz um 0.27% gestiegen.
Was ist die größte Einnahmequelle von Jazz Pharmaceuticals PLC?
Am FY2025Q2 erzielte das Geschäft mit Xywav für Jazz Pharmaceuticals PLC den höchsten Umsatz in Höhe von 415.32M, was 39.72% des Gesamtumsatzes entspricht.
